Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

More documents

Recommendations

Info

144 10° CONGRESSO NAZIONALE SIMIT Abstract 50 - SEMPLIFICAZIONE TERAPEUTICA CON IP NON BOOSTERATO: È UNA SCELTA SICURA? ESPERIENZA DI UN CENTRO CLINICO. - Riccio C. [1] , Penco G.* [2] , Nigro N. [1] , Caligiuri P. [3] , Pontali E. [2] , Bruzzone B. [1] , Cassola G. [2] - [1] Divisione di Igiene - Osp. S. martino ~ Genova - [2] S.C. Malattie Infettive - Ospedale Galliera ~ Genova - [3] DIpartimento di Scienze della Salute - Università di Genova ~ Genova INFEZIONI DA HIV Premessa: L‟esposizione prolungata alla TARV può causare dislipidemia e lipodistrofia.Tra gli IP, Atazanavir (ATV) unboosted sembra avere il più basso impatto metabolico. Obiettivo del ns. studio era di valutare sicurezza ed efficacia di un regime terapeutico contenente ATV unboosted in pz experienced (EXP). Obiettivo: Abbiamo valutato retrospettivamente una coorte di 30 pz HIV+ (18 F; età media 48 aa).I pz erano arruolati con viremia (CV)
145 10° CONGRESSO NAZIONALE SIMIT Abstract 53 - THE 10 YEAR SAFETY AND EFFICACY OF A TENOFOVIR DISOPROXIL FUMARATE (TDF) –CONTAINING ONCE-DAILY HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) - Cassetti I. [1] , Madruga J. [2] , Etzel A. [2] , Suleiman J. [3] , Rhee M. [4] , Warren D. [4] , Picaro L.* [5] - [1] Foundation Centro Estudios Infectologicos ~ Buenos Aires - [2] Centro de Referencia e Treinamento DST/AIDS ~ Sao Paulo - [3] Hospital Guilherme Alvaro ~ santos - [4] Gileas Sciences ~ FOster City - [5] Gilead Sciences SRL ~ Milano INFEZIONI DA HIV Premessa: Study 903 was a Phase III randomized double-blind (DB) 3 year study comparing TDF to stavudine (d4T) each in combination with lamivudine (3TC) and efavirenz (EFV) in HIV-1 infected antiretroviral naïve patients. TDF was associated with durable efficacy and safety (better lipid profile, and less lipodystrophy and peripheral neuropathy). A subset of these patients now provides 10 years of longitudinal efficacy and safety data of TDF-containing once-daily HAART Obiettivo: Subjects in Argentina, Brazil, and the Dominican Republic who completed the 3 year DB period of study were eligible to roll-over into an open-label (OL) study (Study 903E) of the once-daily HAART regimen, TDF+3TC+EFV. At OL baseline, 86 subjects previously receiving TDF in the DB study were randomized to continue to receive TDF (62% male, 70% white, mean age 33 yrs). At OL baseline, 85 subjects were switched from d4T to TDF (60% male, 64% white, mean age 37 yrs). The results reflect only the period of TDF exposure. Risultati: Duration of exposure to TDF was 480 weeks for patients continuing TDF and 336 for those switched to TDF. HIV RNA < 50 (copies/mL) at Week 480 (ITT, Missing = Failure) was 63% and 64% respectively. HIV RNA < 50 (copies/mL) at Week 480 (ITT, Missing = Excluded) was 92% and 96% respectively. Change in mean (SD) CD4, was +545 (237) and +180 (290) cells/mm3, respectively. Change in mean (SD) in estimated Creatinine Clearance (Cockcroft-Gault equation), was +2.5 (23.4) and -10.7 ml/min (22.6). Median limb fat at year 10 was 10.4 and 7.5 kg, respectively. Conclusione: Antiretroviral-naïve subjects who received TDF-containing once-daily HAART for up to 10 years demonstrated sustained virologic and immunologic benefit, improved limb fat, stable renal function, and their BMD remained stable after a clinically insignificant decrease that occurred during the first year of TDF therapy.
Page 1 and 2:
Abstract 230 - IMPIEGO DEI GLICOPEP
Page 3 and 4:
Abstract 223 - VANCOMICINA IN INFUS
Page 5 and 6:
5 10° CONGRESSO NAZIONALE SIMIT Ab
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
11 10° CONGRESSO NAZIONALE SIMIT A
Page 13 and 14:
Azithromycin R 2 Gentamicin S 1 Van
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Abstract 9 - SIEROPREVALENZA DELL
Page 29 and 30:
Page 31 and 32:
Abstract 170 - MALATTIA DI LYME A B
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Abstract 144 - EPIDEMIA DI TRICHINE
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
16 Legati al paziente 4 Non identif
Page 59 and 60:
Page 61 and 62:
Nausea 24 % Rinorrea 21 % Congiunti
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
75 10° CONGRESSO NAZIONALE SIMIT F
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Via di trasmissione TD vs altre 65.
Page 83 and 84:
Abstract 194 - LESIONE EPIGLOTTICA
Page 85 and 86:
Page 87 and 88:
Page 89 and 90:
Page 91 and 92:
Page 93 and 94: 93 10° CONGRESSO NAZIONALE SIMIT A
Page 101 and 102: 101 10° CONGRESSO NAZIONALE SIMIT
Page 109 and 110: Genere maschile, n 30 (58%) Età me
Page 137 and 138: TAS>51 TAS95%, n (%) 19 (61,3) 13 (
Page 143: 143 10° CONGRESSO NAZIONALE SIMIT
Page 161 and 162: Abstract 262 - SINDROME DI LYELL IN
Page 171 and 172: Abstract 117 - POTENZIALITÀ RIPROD
Page 173 and 174: Abstract 137 - INFEZIONI DA HBV, HC
Page 191 and 192: Demografiche Comorbidità Sintomi d
Page 193 and 194: Neisseria Meningitidis S. Pneumonia
Page 195 and 196:
195 10° CONGRESSO NAZIONALE SIMIT
Page 197 and 198:
Page 199 and 200:
Page 201 and 202:
Page 203 and 204:
Page 205 and 206:
Page 207 and 208:
Page 209 and 210:
Page 211 and 212:
Page 213 and 214:
Page 215 and 216:
Page 217 and 218:
Page 219 and 220:
Page 221 and 222:
Page 223 and 224:
Page 225 and 226:
Page 227 and 228:
Page 229 and 230:
Page 231 and 232:
Page 233 and 234:
Page 235 and 236:
Page 237 and 238:
Page 239 and 240:
Abstract 55 - EPATITE VIRALE ACUTA
Page 241 and 242:
Page 243 and 244:
Page 245 and 246:
Page 247 and 248:
Page 249 and 250:
Page 251 and 252:
Page 253 and 254:
Page 255 and 256:
Page 257 and 258:
IL28b: CC HCVRNA UI/L, mediana (IQR
Page 259 and 260:
Page 261 and 262:
Page 263 and 264:
Abstract 23 - UN CASO INUSUALE DI I
Page 265 and 266:
Page 267 and 268:
Page 269 and 270:
Page 271 and 272:
Page 273 and 274:
Page 275 and 276:
Page 277 and 278:
Page 279 and 280:
Page 281 and 282:
KIR2DL1 - HLA-C2 car 31/41 (75.6%)
Page 283 and 284:
Page 285 and 286:
Page 287 and 288:
Page 289 and 290:
Page 291 and 292:
Page 293 and 294:
Page 295 and 296:
Abstract 305 - STREPTOCOCCAL SHOCK
Page 297 and 298:
Page 299 and 300:
Page 301 and 302:
Page 303 and 304:
Page 305 and 306:
Page 307 and 308:
Study ID Greif (2000) Pryor (2004)
Page 309 and 310:
Page 311 and 312:
Page 313 and 314:
Page 315 and 316:
Page 317 and 318:
Page 319 and 320:
Page 321 and 322:
Page 323 and 324:
Page 325 and 326:
Page 327 and 328:
Abstract 89 327 10° CONGRESSO NAZI
Page 329 and 330:
Page 331 and 332:
Abstract 72 - GRAVE QUADRO DI IRIS
Page 333 and 334:
show all

Abstract 230 - IMPIEGO DEI GLICOPEPTIDI NELLA ... - SIMIT

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?